Pimasertib

Drug Profile

Pimasertib

Alternative Names: AS-703026; EMD-1036239; MSC 1936369; MSC 1936369B; MSC1936369A

Latest Information Update: 10 Dec 2016

Price : $50

At a glance

  • Originator Santhera Pharmaceuticals
  • Developer Merck Serono; Sanofi
  • Class Amides; Aminopyridines; Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Discontinued Colorectal cancer; Haematological malignancies; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 10 Dec 2016 Adverse events and efficacy data from a phase II trial in Malignant melanoma (First-line therapy, Late-stage disease, Metastatic disease) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 24 Aug 2016 EMD Serono terminates a phase-I/II clinical trial in Colorectal cancer (Second-line or greater therapy, Combination therapy, Metastatic disease) in Spain, Belgium and Italy (PO) (NCT01085331)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top